FDA Brief

Warning letters Devices

FDA warning letter to

Workswell Group s.r.o.

High riskIssued Mar 4, 2021Posted Mar 5, 2021Center for Devices and Radiological Health

FDA warned Workswell Group that its MEDICAS thermal camera was sold in the U.S. for COVID-19 screening without FDA approval.

What happened

FDA reviewed Workswell's website and social media pages on February 19, 2021, and found the MEDICAS thermal camera offered for sale in the United States. The pages said the camera could detect viral diseases including SARS-CoV2 and diagnose abnormal temperatures, and could scan unlimited people at once. FDA said the product was sold without marketing approval, clearance, or authorization.

What FDA found

  1. The MEDICAS is offered for sale in the United States without FDA marketing approval, clearance, or authorization.

    Section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)
  2. The company did not have an approved premarket approval application or an investigational device exemption for the device.

    Section 515(a), 21 U.S.C. § 360e(a); Section 520(g), 21 U.S.C. § 360j(g)
  3. FDA calls the product misbranded because the company did not notify FDA of its intent to market it, as required by the 510(k) process.

    Section 502(o), 21 U.S.C. § 352(o); Section 510(k), 21 U.S.C. § 360(k)
  4. FDA said introduction or delivery of the product into interstate commerce is prohibited.

    Section 301(a), 21 U.S.C. § 331(a)

What FDA wants

Within 48 hours, email COVID-19-Task-Force-CDRH@fda.hhs.gov with the steps taken to address the violations, how the company will prevent them from recurring, and supporting documents. If the company cannot act completely within 48 hours, it must state why and give a time when it will; if it believes the product is not in violation, it must include its reasoning and supporting information.

Who should pay attention

  • distributors and resellers of thermal screening cameras
  • venues using temperature screening for entry
  • buyers of COVID-19-related medical devices

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AseptiKits, LLC

    AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.

    High risk
  2. Happiest Baby, Inc.

    FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.

    High risk
  3. Estar Technologies Ltd

    FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

    High risk
  4. ProDx Health

    FDA warns ProDx Health that its HIV sample self-collection kits are sold without marketing authorization.

    High risk